Binding, uptake, and transport of hypericin by Caco-2 cell monolayers.
The biological evaluation of hypericin in various test models is hampered by its very poor water solubility. In the present study cyclodextrin formulations and liposomal preparations were investigated for improved delivery and solubility of hypericin in aqueous buffer systems. Caco-2 cells, grown to tight monolayers on 96-well tissue culture plates as well as on Transwell polycarbonate filters, were used to study the membrane binding and the epithelial transport of hypericin. Cumulative transport of hypericin, which could not be measured without the use of cyclodextrins, in apical-to-basolateral direction from cyclodextrin-hypericin buffer solutions was 3-5% at 37 degrees C and approximately 0.12% at 4 degrees C after 5 h. After an incubation time of 1 h at 37 and 4 degrees C, 12.7% +/- 2.6% and 6.5% +/- 0.8%, respectively, of hypericin were found to be bound to or taken up by Caco-2 cells. Liposomal formulations markedly increased the solubility of hypericin in Krebs-Ringer buffer, but there was no effect observed on the binding and transport of hypericin delivered by liposomes in the Caco-2 cell model. Due to the fluorescence properties of hypericin, its interaction with the cells could be visualized by confocal laser scanning microscopy. The results indicate that a significant accumulation of the drug in the cell membrane and the cell nucleus membrane takes place. We conclude that hypericin is absorbed through the intestinal epithelium by passive transcellular diffusion and that increasing its solubility by cyclodextrin appears as a promising approach to increase its oral bioavailability for pharmaceutical formulations.
Sattler
S
S
Department of Biopharmaceutics and Pharmaceutical Technology, University of the Saarland, Saarbruecken, Germany.
Schaefer
U
U
Schneider
W
W
Hoelzl
J
J
Lehr
C M
CM
D000873:Anthracenes; D000928:Antidepressive Agents / Q000378:metabolism* / Q000493:pharmacokinetics*; D000998:Antiviral Agents / Q000378:metabolism* / Q000493:pharmacokinetics*; D001692:Biological Transport; D018938:Caco-2 Cells / Q000378:metabolism*; D003505:Cyclodextrins / Q000494:pharmacology; D004347:Drug Interactions; D006801:Humans; D008081:Liposomes; D018613:Microscopy, Confocal; D010569:Perylene / Q000031:analogs & derivatives* / Q000378:metabolism / Q000493:pharmacokinetics; D012995:Solubility; D013056:Spectrophotometry, Ultraviolet
D000873:Anthracenes; D000928:Antidepressive Agents; D000998:Antiviral Agents; D003505:Cyclodextrins; D008081:Liposomes; D010569:Perylene; C004965:hypericin